Bishop’s Stortford woman Jo Doyle blogs about life with Lyme disease AND coronavirus
New Delhi: The Indian Council of Medical Research (ICMR), the country’s apex body in the field, has found that consuming the drug hydroxychloroquine reduces the chances of getting infected with Covid-19.
As a result, ICMR released an advisory Friday to expand the usage of HCQ — an anti-malarial drug — as a preventive treatment against the novel coronavirus.
The conclusion has been drawn on the basis of three studies conducted by the ICMR.
The advisory suggests surveillance workers, paramilitary and police personnel, as well as medical staff working in non-Covid hospitals and blocks to start consuming the pill as “preventive therapy”. (See link for article)
____________________
For more: https://madisonarealymesupportgroup.com/2020/06/06/fraudulent-hcq-covid-19-study-in-lancet-exposed/
https://madisonarealymesupportgroup.com/2020/06/01/rebuttal-on-huge-hcq-study-in-lancet/
https://www.corbettreport.com/gates/ (Videos and full transcripts within link)
Catherine Austin Fitts of solari.com interviews James Corbett about his new documentary, Who Is Bill Gates? They go beyond the focus on Gates to discuss the syndicate that he is leading, the business model it relies on, and the new form of collateral that will underlie the digital economy: the human body. Don’t miss this vital conversation that fills in the missing pieces of the puzzle and draws back the curtains on the real purpose of the injection fraud.
SHOW NOTES AND MP3: https://www.corbettreport.com/?p=36739
https://madisonarealymesupportgroup.com/2020/04/29/gates-patent-for-body-activity-data-apparatus/
https://madisonarealymesupportgroup.com/2020/03/30/the-national-plan-to-vaccinate-every-american/
https://madisonarealymesupportgroup.com/2020/05/13/house-resolution-6666-traceact/
https://pubmed.ncbi.nlm.nih.gov/32208532/
doi: 10.1111/trf.15752. Online ahead of print.
Abstract
Tick-borne agents of disease continue to emerge and subsequently expand their geographic distribution. The threat to blood safety by tick-borne agents is ever increasing and requires constant surveillance concomitant with implementation of appropriate intervention methods. In April 2017, the Food and Drug Administration organized a public workshop on emerging tick-borne pathogens (excluding Babesia microti and Lyme disease) designed to provide updates on the current understanding of emerging tick-borne diseases, thereby allowing for extended discussions to determine if decisions regarding mitigation strategies need to be made proactively. Subject matter experts and other stakeholders participated in this workshop to discuss issues of biology, epidemiology, and clinical burden of tick-borne agents, risk of transfusion-transmission, surveillance, and considerations for decision making in implementing safety interventions. Herein, we summarize the scientific presentations, panel discussions, and considerations going forward.
____________________
**Comment**
I only had access to the abstract, but Dr. Cameron writes more fully on the workshop here: https://danielcameronmd.com/babesia-infection-transmitted-blood-supply/
Interestingly, according to the abstract, they excluded Babesia and Lyme, which are arguably two of the largest problems. It was pointed out that 200 cases of Babesia were transmitted through blood transfusions at the time of the workshop and that Anaplasma is next with increasing clinical cases.
Evidently there have been no reported cases of Lyme transmitted through the blood supply.
Other tick-borne pathogens have been transmitted through donated blood, but these occurrences are rare. (Or rarely reported)
In addition, “two emerging [tick-borne agents] − B. miyamotoi and Powassan virus were discussed − for B. miyamotoi,cases have steadily increased since 2014.”
For more: https://madisonarealymesupportgroup.com/2019/07/28/tick-borne-infection-risk-in-blood-transfusion/
https://madisonarealymesupportgroup.com/2016/06/02/study-showing-results-testing-babesia-microti/
https://danielcameronmd.com/babesia-microti-imported-foreign-countries/
Over the past two decades, there have been reports of the tick-borne infection Babesia microti being imported into foreign countries from the United States. International travelers are unknowingly carrying the disease into countries, which may be unfamiliar with diagnosing tick-borne illnesses.
“Recently, sporadic cases of human babesiosis caused by several species of Babesia have been reported in other countries,” write the authors of “Imported Human Babesiosis, Singapore, 2018.” [1] These cases include:
Additionally, in 2003, Nohýnková and colleagues reported what was believed to be the first case of symptomatic Babesia microti infection imported into the Czech Republic from the United States. [2] Meanwhile in 2013, investigators described the “first human case of Babesia microti infection imported to Denmark from the United States by a 64-year-old female traveler with fever of unknown origin.” [3]
READ MORE: Tourists visiting the United States contract Babesia, leaving one dead
According to the authors, “The case raises the possibility that Babesia infections may be under-diagnosed, [and] illustrates the importance of a thorough travel history…” [3]
The number of international travelers carrying tick-borne diseases into foreign countries is rising, making it increasingly important for clinicians to gather a thorough travel history on patients. CLICK TO TWEET
Two recent case reports demonstrate the rise of tick-borne diseases being imported into other countries and highlights the challenges clinicians face in distinguishing these illnesses, specifically Babesia microti, from malaria.
Case 1: Singapore
A 37-year-old man traveled to multiple places in the year before his illness. His travel history included Vietnam, Thailand, Indonesia, Cambodia, Indonesia, and the United States.
On June 17, 2018, after visiting the Northeastern USA, he noted a right ankle papule that lasted 3 weeks. “He sought consultation at a travel clinic [in Singapore] because of high fever (104°F), rigors, and headaches, which had persisted and worsened over 18 days,” writes Lim and colleagues. [1]
Doctors had prescribed amoxicillin, but the symptoms persisted.
LISTEN TO PODCAST: Babesia treatment of two travelers
“Laboratory test results revealed moderate thrombocytopenia and anemia, and malaria blood films revealed trophozoites forming in erythrocytes, suggestive of Babesia,” writes Lin.
The doctors confirmed the diagnosis of Babesia microti with additional testing. He was treated successfully with quinine and clindamycin.
Case 2: Spain
“A 72-year-old man with a 15-day history of fever, generalized arthralgia, asthenia, and decreased appetite was admitted to Hospital Universitario San Cecilio, Granada, Spain,” writes Guirao-Arrabal and colleagues in “Imported babesiosis caused by Babesia microti − A case report.” [4]
The man had a history of sweating and his inflammatory markers were elevated. He also had a history of type 2 diabetes.
He reportedly traveled to a park in Westchester County, NY, an area that is considered endemic for babesiosis.
Malaria was considered based on intraerythrocytic forms in the red cells. The malaria antigen and PCR tests for malaria were negative.
Babesia microti was presumed with a low level of parasitemia (0.5 %). There was no evidence of another tick-borne illness. After treatment with atovaquone and azithromycin, his parasitemia resolved.
Editor’s note: It is encouraging to see that Babesia is now being considered by clinicians and treated appropriately.
_______________________
For more: https://madisonarealymesupportgroup.com/category/babesia-treatment/